Sequoia gains $35M in third round
The Wellcome Trust has led a $35 million third round of venture capital for Sequoia Pharmaceuticals, which has been developing a therapy for drug-resistant HIV. MedImmune Ventures also jumped in as a new investor in the company. Much of the money is earmarked for product development.
- here's the release on the venture round
ALSO: Kleiner Perkins Caufield & Byers Pandemic & Biodefense Fund has added $6 million to Juvaris BioTherapeutics' first venture round. The money goes to pushing its lead vaccine products for influenza and pneumonia indications into clinical trials. Release
Be the first to comment
More stories about pharmaceuticals Venture Capital pandemic MedImmune Kleiner Perkins Caufield & Byers biodefense
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage
